All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation or HealthTree for Multiple Myeloma.
Bookmark this article
The Multiple Myeloma Hub was pleased to speak to Shaji Kumar, Mayo Clinic, Rochester, US, and Naresh Bumma, The Ohio State University, Columbus, US. We asked, How to select maintenance therapies post-autologous stem cell transplant (ASCT) for patients with high-risk MM?
How to select maintenance therapies post-ASCT for patients with high-risk MM?
In this expert discussion, Shaji Kumar and Naresh Bumma provide their insights into post-ASCT maintenance therapy for high-risk patients. The experts consider the use of lenalidomide as a monotherapy versus in combination with a proteosome inhibitor, whilst sharing their thoughts on the challenges in defining the high-risk population.
Kumar and Bumma present their individual management strategies for this patient population and examine existing clinical data, highlighting the need for prospective trials. This discussion concludes with a look to the future management of high-risk multiple myeloma post-ASCT.
The impact of second primary and second hematological malignancies on survival outcomes of MM after auto-HSCT
Here we summarize a retrospective cohort analysis on the clinical impact of SPMs and SHMs on PFS and OS in patients with MM who underwent...
Prognostic impact of MRD dynamics during maintenance therapy for patients with NDMM
We summarize a pooled analysis of the phase III TOURMALINE-MM3 and -MM4 trials evaluating the prognostic value of MRD dynamics in transplant eligible and...
Chronic opioid use following auto-HSCT in patients with MM
We summarize a presentation from TCT 2023 on a retrospective analysis of the prevalence and effect on outcomes of chronic opioid use following auto-HSCT in patients with MM.
Subscribe to get the best content related to multiple myeloma delivered to your inbox